Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results entities : Genmab a::S save search
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: 2024-02-27 (Crawled : 21:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: -4.56%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: -2.51%
H: 0.07%
C: -2.3%
employee
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
Published: 2024-01-30 (Crawled : 12:30) - biospace.com/
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 2.14%
H: 1.03%
C: -0.89%
ALPMF | $9.48 -8.41% 43.47% 22
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: 0.0%
ALPMY | $9.2715 -2.92% -1.11% 500K
|
Manufacturing
|
| O: -3.53%
H: 3.49%
C: 3.4%
PFE A | $25.91 0.19% -0.19% 28M
|
Health Technology
|
| O: 1.49%
H: 1.72%
C: -3.12%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: 0.42%
H: 0.04%
C: -0.99%
ARVN | $34.72 -4.33% -4.58% 650K
|
Health Technology
|
| O: -0.46%
H: 0.79%
C: 0.28%
financial results
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: 2023-12-05 (Crawled : 23:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 1.42%
H: 2.7%
C: 0.28%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: 2.84%
H: 0.68%
C: -0.03%
employee
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 6.62%
H: 2.29%
C: -0.06%
ZLAB | $14.2 -0.77% -0.88% 640K
|
Health Technology
|
| O: 8.3%
H: 0.02%
C: -2.12%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: -0.57%
NVCR | $12.72 -6.26% -6.68% 890K
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: -6.94%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.29%
H: 0.21%
C: -0.48%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.27%
H: 0.14%
C: -3.34%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: 7.35%
H: 0.44%
C: -2.18%
results
Genmab Announces Financial Results for the First Nine Months of 2023
Published: 2023-11-07 (Crawled : 16:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 0.39%
H: 4.92%
C: 1.52%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 0.24%
H: 0.18%
C: 0.16%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: 0.24%
H: 3.44%
C: 2.07%
BNTX | $87.89 1.63% 1.59% 710K
|
Health Technology
|
| O: -0.35%
H: 3.09%
C: 3.03%
financial results
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 0.24%
H: 3.29%
C: -1.11%
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
PFE A | $25.91 0.19% -0.19% 28M
|
Health Technology
|
| O: 0.19%
H: 0.29%
C: -0.45%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: 0.55%
H: 0.44%
C: -1.37%
BNTX | $87.89 1.63% 1.59% 710K
|
Health Technology
|
| O: 5.74%
H: 3.18%
C: -1.55%
update financial results
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: 2023-09-12 (Crawled : 18:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: -1.23%
H: 1.88%
C: 1.24%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: -1.6%
H: 0.55%
C: -0.11%
employee
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: 2023-08-15 (Crawled : 17:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 0.98%
H: 0.89%
C: -0.81%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: -0.11%
H: 0.34%
C: -0.19%
employee
Genmab Announces Financial Results for the First Half of 2023
Published: 2023-08-03 (Crawled : 15:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 0.24%
H: 1.29%
C: 1.29%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: -0.28%
H: 0.27%
C: 0.06%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: -2.25%
H: 1.87%
C: 1.52%
BNTX | $87.89 1.63% 1.59% 710K
|
Health Technology
|
| O: -0.25%
H: 3.13%
C: 1.84%
financial results
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-06-27 (Crawled : 23:00) - prnewswire.com
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: -1.28%
H: 0.97%
C: 0.86%
cd20 duobody abbvie positive topline trial results
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-06-27 (Crawled : 23:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: -1.43%
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: -1.28%
H: 0.97%
C: 0.86%
cd20 duobody abbvie positive topline trial results
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: 2023-06-20 (Crawled : 19:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: -4.22%
H: 5.82%
C: 3.93%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: -0.88%
H: 0.72%
C: 0.32%
employee
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: 2023-05-23 (Crawled : 19:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: -1.04%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: -1.39%
H: 0.0%
C: -1.31%
employee
Genmab Announces Financial Results for the First Quarter of 2023
Published: 2023-05-10 (Crawled : 14:20) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 0.92%
H: 0.54%
C: -0.64%
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: -1.24%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: -1.03%
H: 0.26%
C: 0.01%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.09%
H: 0.48%
C: 0.28%
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: -0.21%
H: 0.32%
C: -0.07%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: 0.15%
H: 2.12%
C: 1.79%
BNTX | $87.89 1.63% 1.59% 710K
|
Health Technology
|
| O: -1.6%
H: 1.64%
C: -0.39%
financial results
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published: 2023-03-29 (Crawled : 22:00) - globenewswire.com
FNCTF | $11.128 -0.29% -20.84% 0
|
Communications
|
| O: 1.48%
H: 0.0%
C: 0.0%
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 0.0%
H: 1.69%
C: 1.42%
BOLT | $1.13 -5.83% -4.8% 170K
|
|
| O: 5.43%
H: 0.74%
C: -1.47%
BMY | $48.51 0.48% 0.19% 9.8M
|
Health Technology
|
| O: 0.29%
H: 0.22%
C: -0.26%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: 0.37%
H: 0.05%
C: -0.4%
business year update financial results
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: 2023-02-28 (Crawled : 20:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 0.74%
H: 0.38%
C: -1.33%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: -0.72%
H: 1.37%
C: -0.8%
employee
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: 2022-12-13 (Crawled : 21:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: -2.05%
H: 1.95%
C: 0.33%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: -1.09%
H: 1.86%
C: 0.92%
employee
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
Published: 2022-12-12 (Crawled : 18:00) - biospace.com/
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 1.4%
H: 2.59%
C: -1.22%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.12%
H: 1.09%
C: 1.07%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: 0.09%
H: 3.47%
C: 2.83%
darzalex results study
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: 2022-11-15 (Crawled : 19:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 0.02%
H: 3.58%
C: 1.34%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: 0.79%
H: 0.55%
C: 0.14%
employee
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: 2022-09-27 (Crawled : 17:00) - globenewswire.com
GNMSF | $282.004 -3.13% 3.83% 210
|
Health Technology
|
| O: 4.98%
H: 0.0%
C: -4.34%
GMAB | $29.51 0.85% 0.85% 460K
|
Health Technology
|
| O: 1.11%
H: 1.29%
C: -0.16%
employee
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.